Table 1.
Comparison of the clinical characteristics and urinary nerve growth factor (NGF), NGF/creatinine (NGF/Cr), brain-derived neurotrophic factor (BDNF), and BDNF/Cr levels between controls and IC/BPS patients.
Figure 1.
The changes of urinary levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF).
The urinary levels of NGF (pg/ml) and BDNF (pg/ml) were compared between baseline and after 6-month treatment of HA (6M) in responders and non-responders based on (A) a visual analogue scale (VAS, for pain) decrease of ≥ 2, (B) global response assessment (GRA) increase of ≥ 2 and (C) functional bladder capacity (FBC) increase of ≥ 50%. Data are expressed as means ± standard deviations.
Table 2.
Comparison of urinary NGF/Cr and BDNF/Cr levels in clinical responders and non-responders after intravesical hyaluronic acid treatment in IC/BPS patients.